(MedPage Today) — SAN FRANCISCO — Adding modified FOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) and bevacizumab (Avastin) to atezolizumab (Tecentriq) significantly improved progression-free survival (PFS) in patients with previously untreated…
Source link : https://www.medpagetoday.com/meetingcoverage/mgics/119392
Author :
Publish date : 2026-01-12 21:39:00
Copyright for syndicated content belongs to the linked Source.
